Dr. Patel on the Potential Utility of Elranatamab in Multiple Myeloma

Partner | Cancer Centers | <b>MD Anderson</b>

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential utility of elranatamab (PF-06863135) in multiple myeloma.

Elranatamab is a bispecific antibody that targets BCMA and CD3, Patel says. Rather than replacing T cells with a new receptor, which is the case with CAR T-cell therapy, bispecific antibodies harness a patient’s own T cells to effectively kill myeloma cells, Patel explains. In the case of elranatamab, CD3 and BCMA push the activated T cells and myeloma cells close together so that the T cells can kill the myeloma cells, Patel says.

Findings from the phase 1 MagnetisMM-1 trial (NCT03269136) demonstrated a 70% overall response rate with elranatamab, dosed at 215 or more µg/kg, in patients with relapsed/refractory multiple myeloma. Although these are early data, they suggest that bispecific antibodies could play a significant role in the treatment of heavily pretreated patients with multiple myeloma, Patel says. Moreover, the agents alone or in combination with other therapies could offer an effective option for patients who have progressed on CAR T-cell therapy or those who are ineligible for CAR T-cell therapy, Patel concludes.